Navigation Links
Life Sciences Leader Joins Millennium Board of Directors
Date:10/4/2007

CAMBRIDGE, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the election of Jeffrey M. Leiden, M.D., Ph.D., to its Board of Directors. Dr. Leiden, a Managing Director at Clarus Ventures, a life sciences venture capital firm, has a distinguished career of more than 20 years of experience in the biomedical and pharmaceutical sectors. Prior to joining Clarus, Dr. Leiden served as President and Chief Operating Officer of the Global Pharmaceutical Business of Abbott Laboratories.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"It is a pleasure to have Dr. Leiden join the Millennium Board of Directors," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "We believe his diverse pharmaceutical and scientific experience will enable him to help guide our continued growth and success in our mission of delivering vital medicines to patients."

Prior to joining Abbott Laboratories in 2000, Dr. Leiden was the Elkan R. Blout Professor of Biological Sciences at Harvard School of Public Health, as well as Professor of Medicine at Harvard Medical School. Before his career at Harvard, he served as Professor of Medicine and Pathology and Chief of Cardiology at the University of Chicago, School of Medicine. Dr. Leiden has also co-founded several biotechnology firms.

"I'm delighted to join Millennium's Board of Directors and begin supporting Millennium's management in continuing to build a leading biopharmaceutical company," said Dr. Leiden. "I look forward to utilizing my experiences and knowledge to further the Company's success and deli
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... PALM BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... GLOBAL MARKETS , the global market for digital polymerase ... 2013. This is estimated to grow to $490 billion ... (CAGR) of 28.6%. , New digital PCR technology has ... the broader PCR field. The opportunities presented by this ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a net loss allocable to common stockholders in ... per share, compared to a net loss allocable to common ... or $0.75 per share. "Receiving the positive lorcaserin BLOOM results ...
... the Digital Arts AllianceBATON ROUGE, La., May 11 ... the second year in a row, Louisiana State University,s ... program with scholarships and digital arts equipment. The 2009 ... video cameras to document their experiences and pass them ...
... FREMONT, Calif., May 11 Quark Pharmaceuticals, ... developing novel RNA interference (RNAi)-based therapeutics, today ... Scientific Officer, presented a study titled, "PF-04523655 ... Retinal Cells Producing Target Gene Knockdown and ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 2Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 3Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3 2Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3 3
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a ... that CEO Mr. Gino Pereira was interviewed on ... in Tampa Florida . Mr. Pereira discusses ... Cedric Harris and how the Wocket™ aims to ... Cedric Harris tells Gino he ...
(Date:7/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) ... Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, ... report to their offering ... Touch-Less Sensing Market to Grow Exponentially. Touch-less sensing ... the companies were unable to leverage this technology ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... that affect blood pressure were recently identified in ... findings of the study, in which Uppsala University ... Web edition of Nature Genetics . ... of cardiovascular disorders. Previous studies have shown that ...
... (LSTM) has been awarded a 1.1m grant by the ... year project to develop a Field Applicable Screening Tool ... in mosquitoes. The two principal methods for control ... insecticide-treated bednets (ITNs) and indoor residual spraying (IRS) of ...
... Louis, MO, May 11, 2009 As the childhood obesity ... early parent and child behaviors contribute to the problem. A ... in the May/June 2009 issue of the Journal of ... signs of satiety in their infants tend to overfeed them, ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2$1.6 million grant to lead development of resistance-detecting field kit 2Does mom know when enough is enough? 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
in vitro Translation, Accessory Products...
Request Info...
Biology Products: